EYWA

What EYWA does

EYWA is a Uruguay-based biotech startup (founded 2022, headquartered in Montevideo) that designs and produces clinical-grade psychedelic active pharmaceutical ingredients (APIs) — Psilocybin, DMT, 5-MeO-DMT, and Bufotenine — for use in scientific research, clinical trials, and commercial pharmaceutical applications targeting mental health disorders including depression, anxiety, PTSD, trauma, and substance addiction. The company serves three primary use-case segments: academic and research institutions, clinical trial operators (Phase 2b/3 sponsors), and commercial pharmaceutical partners, all reached through direct B2B relationships.

The company's underlying platform is a proprietary biosynthesis process that combines metabolic engineering and synthetic biology to produce the target compounds inside two unique microorganisms, rather than via chemical synthesis or plant extraction. This bioreactor-based architecture is positioned to deliver APIs at 95%+ purity with consistent batch quality, scalable output, and a reduced environmental footprint. EYWA emphasizes a "regulatory-first" approach aligned to GMP standards as a core differentiator. Psilocybin, DMT, and 5-MeO-DMT are positioned as available APIs; Bufotenine remains in the strain engineering stage. Beyond APIs, EYWA operates Eywa Academy, an educational hub featuring expert interviews and podcast content on psychedelic-assisted care, and references Waello, an affiliated dual-platform mental health monitoring app built by WeArePalta.

EYWA's revenue model is B2B sale of clinical-grade APIs to research and clinical buyers under quote-based, one-time/license terms; pricing is not publicly disclosed. The company has raised approximately $2.6 million in cumulative funding, anchored by a $2.5 million seed round from Draper Associates (Draper Cygnus) in October 2025 with participation from GridX and Panambi Ventures, on top of a $100,000 round in December 2024 from Eretz.bio, The Ganesha Fund, and Uruguay Innovation Hub. The team is small (1–10 employees) with three named executives: Founder & CEO Victoria Costa Paz, Partner & COO Pablo Salaverria, and Partner & Biotech Process VP Jorge Wenzel. The company is privately held with no parent entity, no public listing, and operates with a stated global ambition anchored in LATAM.

Name

EYWA

Legal name

Eywa

Website

https://eywa.bio

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

EYWA is a Uruguay-based biotech startup producing clinical-grade psychedelic APIs (Psilocybin, DMT, 5-MeO-DMT, Bufotenine) via biosynthesis, supplying research institutions, clinical trial operators, and pharmaceutical partners for next-generation mental health treatments.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Psychedelic API manufacturing
• Biosynthesis pharmaceutical ingredients
• Clinical-grade compounds
• Biotech drug development
• Active pharmaceutical ingredients

Headquarters

HQ city

Montevideo

HQ country

Uruguay

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. API Sales to Research Institutions: Sale of clinical-grade psychedelic active pharmaceutical ingredients (Psilocybin, DMT, 5-MeO-DMT, Bufotenine) to research institutions, pharmaceutical companies, and clinical trial operators

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

EYWA designs and manufactures clinical-grade psychedelic active pharmaceutical ingredients (APIs) — including Psilocybin, DMT, 5-MeO-DMT, and Bufotenine — using a proprietary biosynthesis platform that combines metabolic engineering, synthetic biology, and bioreactor-based bioprocessing with two unique microorganisms. These APIs are sold to research institutions, clinical trial operators, and pharmaceutical companies for use in psychedelic-assisted mental health research and therapy development.

Product overview

EYWA is a clinical-grade psychedelic compounds company pioneering biosynthesis production of APIs (Active Pharmaceutical Ingredients) including Psilocybin, DMT, 5-MeO-DMT, and Bufotenine. The company operates a unified platform combining advanced biomanufacturing technology with metabolic engineering and synthetic biology to produce consistent, sustainable, GMP-standard psychedelic compounds for scientific research, clinical trials, and commercial applications. EYWA's portfolio includes core compound products (Psilocybin, DMT, 5-MeO-DMT, Bufotenine), an educational hub (Eywa Academy) featuring expert content on psychedelic medicine, and an affiliated mental health monitoring app (Waello). The company targets researchers, clinicians, and patients worldwide to enable next-generation mental health treatments.

Differentiator

Problem solved

Functional benefit

Brands

• Eywa Academy: Educational hub featuring expert interviews and educational talks on psychedelics and mental health innovation
• Waello

Products and services

• Psilocybin

Quantifiable outcome

• Sustained antidepressant effects for up to eight weeks with 5-MeO-DMT treatments
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor.

• Drug ScienceminorStrategic or Co-development PartnerListed as a partner/trusted organization in EYWA's network, suggesting collaboration in psychedelic research and education
• Uruguay Innovation HubminorStrategic or Co-development PartnerRegional innovation hub supporting EYWA's operations in Uruguay and Latin America
• Grid xminorStrategic or Co-development PartnerListed as a partner/trusted organization in EYWA's network
• Ganesha LabminorStrategic or Co-development PartnerListed as a partner in EYWA's ecosystem
• AniiminorStrategic or Co-development PartnerListed as a partner in EYWA's network
• Start GlobalminorStrategic or Co-development PartnerListed as a partner in EYWA's network

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Compass Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy (COMP360) for treatment-resistant depression. Direct comparable as a psilocybin-focused player targeting the same therapeutic indications (depression, PTSD) that EYWA supplies APIs into.
• Beckley Psytech: Clinical-stage developer of intranasal 5-MeO-DMT (BPL-003), the same compound EYWA produces via biosynthesis. Direct overlap in the 5-MeO-DMT supply/value chain and target indications (depression, trauma).
• MindMed: Psychedelic medicine biotech developing LSD and MDMA-based therapies. Comparable as a clinical-stage psychedelic drug developer that consumes psychedelic APIs and competes for the same research and clinical-supply wallet.
• atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic therapies (including DMT and psilocybin programs). Comparable as a buyer/developer of psychedelic APIs and as a fellow multi-compound platform play.
• GH Research: Clinical-stage company developing 5-MeO-DMT (GH001) for treatment-resistant depression. Direct overlap in 5-MeO-DMT development and same therapeutic indication that EYWA's API supports.
• Psygen Industries: Canadian GMP manufacturer of psychedelic APIs (psilocybin, MDMA, DMT, LSD). The closest direct competitor to EYWA's core API manufacturing business, with established DEA and Health Canada licensing.
• Filament Health: Botanical psychedelic drug developer and manufacturer of natural psilocybin. Comparable as a psychedelic API supplier (albeit from plant extraction rather than biosynthesis) targeting clinical research and commercial channels.
• Usona Institute: Non-profit sponsor of psilocybin clinical trials and a major buyer of clinical-grade psilocybin APIs. Comparable as both a potential customer for EYWA and a category-defining player in psychedelic API demand.
• Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin (CYB003) and DMT program (CYB004). Comparable as a multi-compound psychedelic drug developer competing for clinical supply and downstream market share.

Broad incumbents

• Amyris: Synthetic biology company that demonstrated how fermentation-based production can disrupt traditional chemistry for complex molecules. Comparable as a synthetic biology manufacturing paradigm precedent, though not in psychedelics specifically.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eywabio/?originalSubdomain=uy
• Instagraminstagram.com/eywa.bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EYWA